Where ideas meet capital

Where ideas meet capital

Investment Focus

As a life sciences investor we offer the most promising healthcare startups smart money from pre-seed to series A, B, C. Our credo is quality before quantity. The HEMEX portfolio consists of carefully selected ventures, we believe will make a remarkable contribution to the healthcare of tomorrow. As an investor, we like to have skin in the game and be involved in the data collection.

We invest in early-stage startups expected to make an exit or go public within the next three to five years. Innovative, highly promising research projects are scouted through HEMEX network at universities and at competitions. From the 300-400 applications we receive yearly, we invest in three to five startups each year.

“As part of our commitment to making a positive impact in the health care sector, we provide financial support to promising startups. Our team will make sure you are well prepared for all fundraising activities.”

Portfolio Companies

Annaida Technologies SA

#fertility #femtech #medtech

Profile

Annaida is a Swiss Healthtech company, who’s developed and patented a NMR technology, able to provide a fast, non-invasive and quantitative embryo screening, giving patients an improved overall IVF experience.

Founders

Gora Conley
CEO & co-founder

Marco Grisi
CTO & co-founder

Indications
  • Infertility treatment
  • Reproductive health
Fundraising

Open for investments for Series A.

ARTIDIS AG

#oncology #ivd

Profile

Artidis is a Swiss Healthtech company, who’s developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization, with a platform that allows physicians to optimize diagnostics.

Founders

Marija Plodinec
CEO & Board Member, Co-Founder

Marko Loparic
CMO & Head of Digital Health, Co-Founder

Philipp Oertle
Head of Research & Development, Co-Founder

Tobias Appenzeller
Head of Quality & Clinical Operations, Co-Founder

Indications

Breast cancer

Fundraising

Open for investments for Series A.

aspivix SA

#femtech #medtech

Profile

Aspivix is a Swiss medical device startup, devoted to women’s healthcare. The company has created a substitute for the tenaculum, in order to improve the Gynecological experience.

Founders

Mathieu Horras
CEO & Co-Founder

David Finci
Co-Founder

Julien Finci
Co-Founder

Indications

IUD procedures

Fundraising

Open for investments for Series A.

BioReperia logo

BioReperia AB

#oncology #ivd

Profile

BioReperia is a Swedish biotech company, based also in Switzerland, dedicated to provide services that accelerate anti-cancer drug discovery, assisting in selecting candidates efficiently and rapidly.

Founders

Lasse Jensen
Co-Founder

Indications

Bladder cancer

Fundraising

Open for investments for Series A.

Cellestia Biotech AG

#oncology #R&D

Profile

Cellestia Biotech is a research and development company that develops innovative first-in-class therapies by selectively inhibiting transcription factors in the cell nucleus in multiple disease areas. Currently, their lead compound CB-103 is in Phase 2 of clinical trials and successfully treating cancer patients who are resistant to multi-drug treatments.

Founders

Rajwinder Lehal
CEO & Co-Founder

Indications

Solid Tumors and Leukemia

Fundraising

Currently not fundraising.

hemotune AG

#dialysis #medtech

Profile

hemotune AG is a spin-off company originating out of the Functional Materials Lab at ETH Zurich. It has designed a multi-target precision medicine blood purification treatment to restore immune balance in septic shock and improve patient outcomes.

Founders

Carlos Mora
Co-Founder

Lukas Langenegger
Co-Founder

Indications

Sepsis

Fundraising

Currently not fundraising.

Hi-D Imaging logo

Hi-D Imaging AG

#cardiovascular #medtech #digitalhealth

Profile

Hi-D imaging is a Swiss medtech startup. HI-D is developing a new technology, supported by AI, that aims to revolutionize the medical imaging sector by reducing pre-operational/surgical planning complexity.

Founders

Özge Karakaş
Co-Founder

Utku Gülan
Co-Founder

Indications
  • Pre-operational surgery.
  • Risk assessment for cardiac operations. 
Fundraising

Open for investments for Seed Series.

inQbator AG

#incubator #accelerator #funding

Profile

inQbator AG is a start-up accelerator that seeks the most promising innovative companies and help them grow through accelerator programs offering hands-on mentoring, specialized services and access to funding.

Founders

HEMEX, BLKB, Launchpad

Inura Medical AG logo

Inura Medical AG

#femtech #pharma

Profile

Inura Medical is a Swiss biopharma company, developing the first-of-a-kind urethral ovulum to treat patients who suffer from overactive bladder (OAB).

Founders

Professor Grant S. Mulholland (†)
Founder

Vanja Ivancevic
CEO

Indications

Overactive bladder

Fundraising

Open for investments for Series A.

Resistell logo

Resistell AG

#ivd #amr

Profile

Resistell is a Swiss medtech startup, working on a solution for SEPSIS. They’ve patented a technology able to deliver AST diagnostic results in hours instead of days, allowing clinicians to halt sepsis by providing the right treatment to the patient on time.

Founders

Danuta Cichocka
CEO, Co-Founder

Giovanni Dietler
Inventor, Co-Founder

Sandor Kasas
Inventor, Co-Founder

Indications

Sepsis

Fundraising

Open for investments for Series B.

Scailyte logo

Scailyte AG

#ivd #digitalhealth

Profile

Scailyte is a Swiss biotech company, the startup, with a data driven approach, is working on a solution that provides unprecedented insight into diseases and enables ultra-sensitive diagnostics by uncovering human’s hidden “single-cell” secrets.

Founders

Peter Nestorov
Co-Founder & CEO

Manfred Claassen
Co-Founder

Indications
  • Sezary Syndrome (CTCL)
  • Endometriosis
  • ARDS
  • Non-small Cell Lung Cancer (NSCLC)
  • DLBCL (CAR-T cells)
Fundraising

Open for investments for Series A.

Sleepiz logo

Sleepiz AG

#medtech

Profile

Sleepiz is a Swiss medtech startup, working on a device that operates in a non-contact fashion and measures movements originating from heart contractions and breathing patterns, as well as body motions with medical grade accuracy.

Founders

Soumya Sunder Dash
Co-Founder & CEO

Max Sieghold
Co-Founder

Marc Rullan
Co-Founder & CTO

Indications
  • Sleep Apnea
  • Chronic respiratory diseases
  • COVID-19
Fundraising

Currently not fundraising.

TOLREMO therapeutics AG

#biotech #oncology

Profile

Tolremo is a Swiss biotechnology company. Based on cutting-edge science and guided by pioneering real-world medicine, the company created a broad cancer drug resistance platform that provides a unique entry point into a major clinical problem.

Founders

Stefanie Flückiger-Mangual
Co-Founder & CEO

Indications

Resistance preventing precision therapies to patients with cancer.

Fundraising

Fundraising Series A2.

We invest

As investor, we see ourselves as a trusted long-term partner for initial and follow-up financing.

The process we follow to select the best startups is a strict multi-step approach, that ensures an efficient, facts-based, thorough and objective selection. It encompasses the entire process from the first meeting to the final exit.

What we expect from startups
Dedicated and focused teams with innovative and game changing technologies in the healthcare sector. Founders with a focus on the development, open for HEMEX’s support and involvement in data collection. Sustainable solution with a realistic business model and market fit.

 

Evaluation process
Potential investment cases will be carefully examined by our investment committee. Moreover, we maintain a large network of external healthcare experts from a variety of fields to ensure that all cases are assessed with appropriate expertise.

If you believe your Startup fits our expectations please send us an email* to ir@hemex.ch or by using the button below:

Apply for investment

* Please be aware that we receive many applications and we try to answer as quick as possible. If you have not heard from us in three weeks it means you have not been selected.

We invest

As investor, we see ourselves as a trusted long-term partner for initial and follow-up financing.

The process we follow to select the best startups is a strict multi-step approach, that ensures an efficient, facts-based, thorough and objective selection. It encompasses the entire process from the first meeting to the final exit.

What we expect from startups
Dedicated and focused teams with innovative and game changing technologies in the healthcare sector. Founders with a focus on the development, open for HEMEX’s support and involvement in data collection. Sustainable solution with a realistic business model and market fit.

 

Evaluation process
Potential investment cases will be carefully examined by our investment committee. Moreover, we maintain a large network of external healthcare experts from a variety of fields to ensure that all cases are assessed with appropriate expertise.

If you believe your Startup fits our expectations please send us an email* to ir@hemex.ch or by using the button below:

Apply for investment

* Please be aware that we receive many applications and we try to answer as quick as possible. If you have not heard from us in three weeks it means you have not been selected.

Get funding

How can we help?

Do you have specific inquires about any of our services? Would you like to know more about us? Or just stop by? Feel free to reach to us, we'd love to hear from you!

Our offices

Hemex AG
Headquarters | Kasernenstrasse 30 | 4410 Liestal | Switzerland

Hemex Germany GmbH
c/o Loeba Treuhand GmbH, Wallbrunnstr. 24 | 79539 Loerrach | Germany 

Hemex, LLC
The 5th Floor |  3801 Avalon Park East Blvd, Suite 200 | Orlando, FL 32828 | USA

Email us

Hemex AG
info@hemex.ch
firstname.lastname@hemex.ch

Hemex Germany GmbH
info@hemex-germany.de
firstname.lastname@hemex-germany.de

Hemex, LLC
info@hemex-us.com
firstname.lastname@hemex-us.com

Call us

Switzerland:

Mo-Fri 09:00-17:00 CET, our headquarters can be reached on (+41) 61-927-28-00

Germany:

Mo-Fri 09:00-17:00 CET, our EU office can be reached on (+49) 1512-568-48-92

USA:

Mo-Fri 7 a.m. to 6 p.m. EST, our headquarters can be reached on (+1) 689-219-8929

Emergencies:

24/7/365 emergency phone numbers: 

(+41) 79-833-73-30 (Switzerland)

(+49) 1512-568-48-92 (Germany)